--- title: "PDS Biotechnology (PDSB) news: reverse split and offering" url: "https://aibio.space/companies/pds-biotechnology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PDSB reverse split, offering, convertible notes and Nasdaq notice news: PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January…" --- PDSB PDS Biotechnology Corporation NASDAQ · United States # PDS Biotechnology (PDSB) news PDSB reverse split, offering and convertible notes news Debt Financing · 2026-08-31 ## [PDS Biotechnology amends $6,000,000 promissory note](https://aibio.space/news/pds-biotechnology-amends-6-000-000-promissory-note/) PDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment. ## Latest PDS Biotechnology news 1. 2026-08-25 Distress [PDS Biotechnology to cut about 36% of workforce, removes Chief Operating Officer](https://aibio.space/news/pds-biotechnology-cut-about-36-percent-workforce-removes-chief/) PDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer. 2. 2026-07-31 Listings [PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027](https://aibio.space/news/pds-biotechnology-gets-nasdaq-minimum-bid-price-deficiency-letter-has/) Nasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option. 3. 2026-06-15 Debt Financing [PDS Biotechnology closes $6,000,000 note with YA II PN](https://aibio.space/news/pds-biotechnology-closes-6-000-000-note-ya-ii-pn/) PDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program. 4. 2026-04-30 Debt Financing [PDS Biotechnology agrees to sell $6,000,000 promissory note](https://aibio.space/news/pds-biotechnology-agrees-sell-6-000-000-promissory-note/) The 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share. 5. 2025-05-02 Debt Financing [PDS Biotechnology sells convertible debentures for $20,000,000 to retire Horizon loan](https://aibio.space/news/pds-biotechnology-sells-convertible-debentures-20-000-000-retire/) PDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel. ## PDS Biotechnology at a glance - **Ticker**: PDSB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.6 million ### Related companies - [Scorpius Holdings](https://aibio.space/companies/scorpius/) OTC: SCPX - [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) NASDAQ: AVTX - [TETRALOGIC PHARMACEUTICALS CORP](https://aibio.space/companies/tetralogic-pharmaceuticals/) OTC: TLOG - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) NASDAQ: AQST - [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP - [Evommune](https://aibio.space/companies/evommune/) NYSE: EVMN ### Also on NASDAQ - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) PRAX - [Heartflow](https://aibio.space/companies/heartflow/) HTFL - [Cytosorbents](https://aibio.space/companies/cytosorbents/) CTSO - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) MGX - [PHIBRO ANIMAL HEALTH CORP](https://aibio.space/companies/phibro-animal-health/) PAHC - [Spectral AI](https://aibio.space/companies/spectral-ai/) MDAI ## PDS Biotechnology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$19.0 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | [$22.6 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | | Net income (loss) | [-$34.5 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | [-$37.6 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | | Cash from operations | [-$27.8 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | [-$35.0 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | | Cash and equivalents | [$26.7 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126032824/) | [$41.7 million](https://www.sec.gov/Archives/edgar/data/1472091/000114036126012030/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PDS Biotechnology Did PDS Biotechnology do a reverse stock split? Our latest story on this, dated Jul 31, 2026: "PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pds-biotechnology-gets-nasdaq-minimum-bid-price-deficiency-letter-has/). Has PDS Biotechnology raised money recently? Our latest story on this, dated Aug 31, 2026: "PDS Biotechnology amends $6,000,000 promissory note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pds-biotechnology-amends-6-000-000-promissory-note/). Has PDS Biotechnology sold convertible notes? Our latest story on this, dated May 2, 2025: "PDS Biotechnology sells convertible debentures for $20,000,000 to retire Horizon loan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pds-biotechnology-sells-convertible-debentures-20-000-000-retire/). Has PDS Biotechnology received a Nasdaq deficiency notice? Our latest story on this, dated Jul 31, 2026: "PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pds-biotechnology-gets-nasdaq-minimum-bid-price-deficiency-letter-has/). What is the ticker symbol of PDS Biotechnology? PDS Biotechnology Corporation trades under the ticker PDSB on NASDAQ. Where is PDS Biotechnology listed? PDS Biotechnology Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:EU6; LS:A2PF3F; LSX:A2PF3F. What is the SEC CIK of PDS Biotechnology? The SEC Central Index Key (CIK) for PDS Biotechnology Corporation is 1472091. Its filings are on SEC EDGAR. How many shares does PDS Biotechnology have outstanding? 55,971,338 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is PDS Biotechnology listed under? Our directory records PDS Biotechnology Corporation under United States. What does PDS Biotechnology do? Our directory classifies PDS Biotechnology Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of PDS Biotechnology? The ISIN recorded for PDS Biotechnology Corporation is US70465T1079. Does aibio.space cover PDS Biotechnology? aibio.space lists PDS Biotechnology Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is PDS Biotechnology incorporated? SEC records list its state or country of incorporation as DE. Is PDS Biotechnology profitable? PDS Biotechnology Corporation reported a net loss of $34.5 million for the fiscal year ended Dec 31, 2025, and used $27.8 million of cash in operations, per its annual report to the SEC. How much does PDS Biotechnology spend on research and development? $19.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: PDS Biotechnology Members talk about PDS Biotechnology (PDSB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PDS Biotechnology, newest first. Each line links the filing it comes from. 1. 2026-10-14 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126039595/ny20083600x1_s3.htm) 2. 2026-09-14 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/ef20081956_ex99-1.htm) 3. 2026-09-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126035809/ef20081442_8k.htm) 4. 2026-08-25 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126034320/ef20081077_8k.htm) 5. 2026-07-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126030497/ef20079199_8k.htm) 6. 2026-07-21 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126029135/ny20077374x3_424b4.htm) 7. 2026-07-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126028217/ny20077374x1_s3.htm) 8. 2026-06-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126025207/ef20076071_8k.htm) 9. 2026-06-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126023698/ef20075449_8k.htm) 10. 2026-05-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126018464/ef20072168_8k.htm) 11. 2026-03-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm) 12. 2025-11-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036125041557/ny20058850x1_424b5.htm) 13. 2025-05-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036125020483/ny20048867x1_s3.htm) 14. 2025-05-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036125017011/ef20048241_8k.htm) 15. 2025-02-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1472091/000114036125006377/ny20044490x1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PDSB on TradingView](https://www.tradingview.com/symbols/NASDAQ-PDSB/). ## SEC filings and registration - **SEC name**: PDS Biotechnology Corp - **CIK**: 1472091 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PDSB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540 - **Phone**: 800-208-3343 - **Shares outstanding**: 55,971,338 as of 2026-08-06 (10-Q filed 2026-08-13) - **Former names**: Edge Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126040283/ef20084135_8k.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126040181/ef20084000_8k.htm) filed 2026-10-20 - [S-3](https://www.sec.gov/Archives/edgar/data/1472091/000114036126039595/ny20083600x1_s3.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126038728/ef20083341_8k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/ef20082545_8k.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/ef20082538_8k.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/ef20081956_8k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1472091/000114036126035853/ef20081705_8k.htm) filed 2026-09-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001472091), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PDS Biotechnology Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PDSB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PDS Biotechnology Corporation - **Ticker**: PDSB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US70465T1079 - **Other listed symbols**: GETTEX:EU6; LS:A2PF3F; LSX:A2PF3F - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PDSB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pds-biotechnology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PDS Biotechnology (PDSB) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/pds-biotechnology/